Novo Nordisk Launches Oral Weight Loss Drug Wegovy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Source: Fool
- Market Expansion: Novo Nordisk's launch of the oral version of Wegovy marks the first approved oral GLP-1 for chronic weight management, which is expected to help the company regain market share, especially under competitive pressures.
- Competitive Edge: Eli Lilly's orforglipron has shown strong results in weight management and lowering A1C levels in type 2 diabetes patients, with regulatory approval anticipated in Q2, and the company is poised to launch it quickly post-approval, further solidifying its market leadership.
- Patient Appeal: Unlike oral Wegovy, which requires fasting, orforglipron does not impose dietary restrictions, potentially attracting more patients hesitant about injectable treatments, thus expanding the potential market.
- Multiple Indications: Orforglipron is not only aimed at weight loss but may also be approved for diabetes treatment, with its strong performance in aiding type 2 diabetes patients suggesting higher adoption rates among physicians and patients, reinforcing Eli Lilly's dominance in the oral weight loss market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1001.350
Low
950.00
Averages
1192
High
1500
Current: 1001.350
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Plans $3B Investment in China for Supply Chain Expansion
- Marketing Application Submitted: Eli Lilly has submitted a marketing application for its experimental weight loss drug orforglipron to China's National Medical Products Administration, marking a significant step in its market expansion and enhancing its competitiveness in the weight loss drug sector.
- Major Investment Plan: The company plans to invest $3 billion in China over the next decade primarily to expand local production capacity, which will not only enhance supply chain efficiency but also support the localization of its drug pipeline.
- Technological Collaboration: Lilly is collaborating with Beijing-based contract research and manufacturing firm Pharmaron, investing $200 million to enhance its technological capabilities, which will help accelerate the research and production processes for new drugs.
- Market Competition Dynamics: Orforglipron, as Lilly's new product, competes with Novo Nordisk's Wegovy, and is on track for potential FDA approval in Q2 2026, further driving the company's market share in the weight loss drug segment.
See More
AstraZeneca Poised to Acquire Abivax Amid Surge in Valuation
- Acquisition Potential: AstraZeneca is poised to acquire French biotech Abivax, which saw its market value soar to approximately €7.7 billion ($8.9 billion) in 2025 due to strong clinical progress of its lead drug candidate, positioning AstraZeneca as a key player in the pharmaceutical industry's search for innovative therapies.
- Exclusive Data Access: Since early February, AstraZeneca has held exclusive access to Abivax's data room, with the exclusivity period running until March 23, allowing AstraZeneca time to evaluate the data and potentially formalize an acquisition offer; failure to submit a bid by the deadline could reopen negotiations with other interested parties.
- Attractive Drug Candidate: Abivax's drug candidate obefazimod achieved significant breakthroughs in its Phase 3 clinical trials in July 2025, demonstrating impressive efficacy for patients with moderately to severely active ulcerative colitis, with potential commercialization expected around 2027, and the U.S. market anticipated to represent nearly 70% of its commercial opportunity.
- Political and Strategic Edge: As a European company, AstraZeneca may face less political resistance in acquiring Abivax, particularly given the established relationship between its CEO and Abivax's CEO, which could provide strategic advantages during the approval process, especially under the scrutiny of French regulatory authorities.
See More
Novo Nordisk Launches Oral Weight Loss Drug Wegovy
- Market Expansion: Novo Nordisk's launch of the oral version of Wegovy marks the first approved oral GLP-1 for chronic weight management, which is expected to help the company regain market share, especially under competitive pressures.
- Competitive Edge: Eli Lilly's orforglipron has shown strong results in weight management and lowering A1C levels in type 2 diabetes patients, with regulatory approval anticipated in Q2, and the company is poised to launch it quickly post-approval, further solidifying its market leadership.
- Patient Appeal: Unlike oral Wegovy, which requires fasting, orforglipron does not impose dietary restrictions, potentially attracting more patients hesitant about injectable treatments, thus expanding the potential market.
- Multiple Indications: Orforglipron is not only aimed at weight loss but may also be approved for diabetes treatment, with its strong performance in aiding type 2 diabetes patients suggesting higher adoption rates among physicians and patients, reinforcing Eli Lilly's dominance in the oral weight loss market.
See More
Market Dynamics and Investment Strategy Recap
- Inflation Data Impact: On Wednesday, the S&P 500 drifted lower as investors weighed key consumer inflation data against the ongoing U.S.-Iran war and volatile oil prices; although the February CPI report met expectations, concerns about future data intensified, particularly regarding the surge in energy prices driven by the war not reflected in current figures.
- Oil Price Volatility and Market Response: The International Energy Agency announced plans to release 400 million barrels of oil from reserves to address supply disruptions, providing temporary market relief, yet oil prices still rose on Wednesday, indicating ongoing market concerns about energy supply, with Jim Cramer noting a strategy to deploy cash during oversold conditions.
- CrowdStrike Stock Outlook: CrowdStrike shares rose roughly 1% in the morning, but Jim argued the stock should be trading significantly higher due to increasing discussions around AI agents and potential security breaches, particularly with the open-source AI agent OpenClaw gaining popularity in China, emphasizing CrowdStrike's technological edge in this area.
- Eli Lilly Price Target Increase: Wolfe Research raised its price target on Eli Lilly from $1,250 to $1,325, implying about a 32% upside, and while Jim noted investors might overlook this bullish note amid geopolitical uncertainty and inflation concerns, he agreed with the massive market opportunity for Lilly's drug, highlighting that the company is prepared to meet demand with its factories ready.
See More
Market Update: Oil Price Surge and Corporate Earnings
- Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
- Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
- Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
- Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.
See More
Eli Lilly Warns Medicare Patients May Exceed $50 Cap
- Cost Warning: Eli Lilly cautions that some Medicare patients using its GLP-1 weight loss and diabetes medications may end up paying more than the anticipated $50 monthly cap under a new government pricing model, indicating uncertainty in the implementation of Medicare policies.
- BALANCE Initiative Context: This program is part of the Centers for Medicare and Medicaid Services' (CMS) BALANCE initiative, designed to make GLP-1 drugs more affordable by allowing direct negotiations with manufacturers like Eli Lilly and Novo Nordisk, thereby enhancing patient affordability.
- Risk of Cost Variability: While most beneficiaries in participating Medicare plans are expected to pay around $50 per month, Lilly noted that cost-sharing could still vary in a small number of basic Medicare Part D plans, increasing the financial burden risk for patients.
- Market Reaction Focus: Given that changes in Medicare policy could impact patients' medication costs, investors should monitor Eli Lilly and its competitors' performance in the market, particularly regarding profitability and market share under the new pricing model.
See More
Eli Lilly Plans $3B Investment in China for Supply Chain Expansion
- Marketing Application Submitted: Eli Lilly has submitted a marketing application for its experimental weight loss drug orforglipron to China's National Medical Products Administration, marking a significant step in its market expansion and enhancing its competitiveness in the weight loss drug sector.
- Major Investment Plan: The company plans to invest $3 billion in China over the next decade primarily to expand local production capacity, which will not only enhance supply chain efficiency but also support the localization of its drug pipeline.
- Technological Collaboration: Lilly is collaborating with Beijing-based contract research and manufacturing firm Pharmaron, investing $200 million to enhance its technological capabilities, which will help accelerate the research and production processes for new drugs.
- Market Competition Dynamics: Orforglipron, as Lilly's new product, competes with Novo Nordisk's Wegovy, and is on track for potential FDA approval in Q2 2026, further driving the company's market share in the weight loss drug segment.
See More
AstraZeneca Poised to Acquire Abivax Amid Surge in Valuation
- Acquisition Potential: AstraZeneca is poised to acquire French biotech Abivax, which saw its market value soar to approximately €7.7 billion ($8.9 billion) in 2025 due to strong clinical progress of its lead drug candidate, positioning AstraZeneca as a key player in the pharmaceutical industry's search for innovative therapies.
- Exclusive Data Access: Since early February, AstraZeneca has held exclusive access to Abivax's data room, with the exclusivity period running until March 23, allowing AstraZeneca time to evaluate the data and potentially formalize an acquisition offer; failure to submit a bid by the deadline could reopen negotiations with other interested parties.
- Attractive Drug Candidate: Abivax's drug candidate obefazimod achieved significant breakthroughs in its Phase 3 clinical trials in July 2025, demonstrating impressive efficacy for patients with moderately to severely active ulcerative colitis, with potential commercialization expected around 2027, and the U.S. market anticipated to represent nearly 70% of its commercial opportunity.
- Political and Strategic Edge: As a European company, AstraZeneca may face less political resistance in acquiring Abivax, particularly given the established relationship between its CEO and Abivax's CEO, which could provide strategic advantages during the approval process, especially under the scrutiny of French regulatory authorities.
See More
Novo Nordisk Launches Oral Weight Loss Drug Wegovy
- Market Expansion: Novo Nordisk's launch of the oral version of Wegovy marks the first approved oral GLP-1 for chronic weight management, which is expected to help the company regain market share, especially under competitive pressures.
- Competitive Edge: Eli Lilly's orforglipron has shown strong results in weight management and lowering A1C levels in type 2 diabetes patients, with regulatory approval anticipated in Q2, and the company is poised to launch it quickly post-approval, further solidifying its market leadership.
- Patient Appeal: Unlike oral Wegovy, which requires fasting, orforglipron does not impose dietary restrictions, potentially attracting more patients hesitant about injectable treatments, thus expanding the potential market.
- Multiple Indications: Orforglipron is not only aimed at weight loss but may also be approved for diabetes treatment, with its strong performance in aiding type 2 diabetes patients suggesting higher adoption rates among physicians and patients, reinforcing Eli Lilly's dominance in the oral weight loss market.
See More
Market Dynamics and Investment Strategy Recap
- Inflation Data Impact: On Wednesday, the S&P 500 drifted lower as investors weighed key consumer inflation data against the ongoing U.S.-Iran war and volatile oil prices; although the February CPI report met expectations, concerns about future data intensified, particularly regarding the surge in energy prices driven by the war not reflected in current figures.
- Oil Price Volatility and Market Response: The International Energy Agency announced plans to release 400 million barrels of oil from reserves to address supply disruptions, providing temporary market relief, yet oil prices still rose on Wednesday, indicating ongoing market concerns about energy supply, with Jim Cramer noting a strategy to deploy cash during oversold conditions.
- CrowdStrike Stock Outlook: CrowdStrike shares rose roughly 1% in the morning, but Jim argued the stock should be trading significantly higher due to increasing discussions around AI agents and potential security breaches, particularly with the open-source AI agent OpenClaw gaining popularity in China, emphasizing CrowdStrike's technological edge in this area.
- Eli Lilly Price Target Increase: Wolfe Research raised its price target on Eli Lilly from $1,250 to $1,325, implying about a 32% upside, and while Jim noted investors might overlook this bullish note amid geopolitical uncertainty and inflation concerns, he agreed with the massive market opportunity for Lilly's drug, highlighting that the company is prepared to meet demand with its factories ready.
See More
Market Update: Oil Price Surge and Corporate Earnings
- Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
- Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
- Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
- Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.
See More
Eli Lilly Warns Medicare Patients May Exceed $50 Cap
- Cost Warning: Eli Lilly cautions that some Medicare patients using its GLP-1 weight loss and diabetes medications may end up paying more than the anticipated $50 monthly cap under a new government pricing model, indicating uncertainty in the implementation of Medicare policies.
- BALANCE Initiative Context: This program is part of the Centers for Medicare and Medicaid Services' (CMS) BALANCE initiative, designed to make GLP-1 drugs more affordable by allowing direct negotiations with manufacturers like Eli Lilly and Novo Nordisk, thereby enhancing patient affordability.
- Risk of Cost Variability: While most beneficiaries in participating Medicare plans are expected to pay around $50 per month, Lilly noted that cost-sharing could still vary in a small number of basic Medicare Part D plans, increasing the financial burden risk for patients.
- Market Reaction Focus: Given that changes in Medicare policy could impact patients' medication costs, investors should monitor Eli Lilly and its competitors' performance in the market, particularly regarding profitability and market share under the new pricing model.
See More
